Semaglutide
Ozempic, Rybelsus, Wegovy
A long-acting GLP-1 receptor agonist used for type 2 diabetes and obesity management by enhancing insulin secretion and suppressing appetite.
Completed
NCT07043361
Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels
Hillel Yaffe Medical Center
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06499857
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
University of Chicago
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06042153
DIALYSIS-TIR Study
University of Texas Southwestern Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05521256
A Research Study of a New Medicine NNC0113-6856 in Healthy Males
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Enrolling By Invitation
NCT07018544
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
Novo Nordisk A/S
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT05786521
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
The University of Texas Health Science Center at San Antonio
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NA
NCT07035704
Prevent and Reverse Obesity in Children, Adolescents and Young Adults
piero portincasa
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT06161844
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT02212067
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2, PHASE3
NCT05205928
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
McGill University Health Centre/Research Institute of the McGill University Health Centre
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE4
NCT05616052
Comparison of Body Weight Change Through Different Smeglutide Administration Methods
Huashan Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06894784
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
McGill University Health Centre/Research Institute of the McGill University Health Centre
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT04067999
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
Novo Nordisk A/S
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT03021187
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04109547
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05567796
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
BrightGene Bio-Medical Technology Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE3
NCT07271251
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06579105
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
AstraZeneca
INTERVENTIONAL
Updated Dec 15, 2025